Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar;10(3):e329.
doi: 10.1016/S2214-109X(21)00590-8.

Fluvoxamine for the treatment of COVID-19

David R Boulware  1 , Mahsa Abassi  2
Affiliations
Comment

Fluvoxamine for the treatment of COVID-19

David R Boulware et al. Lancet Glob Health. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment in

  • Fluvoxamine for the treatment of COVID-19.
    Kim H, Manzi S, Gonzelez-Heydrich J, Picker J. Kim H, et al. Lancet Glob Health. 2022 Mar;10(3):e330. doi: 10.1016/S2214-109X(22)00003-1. Lancet Glob Health. 2022. PMID: 35180410 Free PMC article. No abstract available.
  • Fluvoxamine for the treatment of COVID-19.
    Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Marzolini C, et al. Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1. Lancet Glob Health. 2022. PMID: 35180411 Free PMC article. No abstract available.

Comment on

References

    1. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10:e42–e51. - PMC - PubMed
    1. Food and Drug Administration COVID-19: developing drugs and biological products for treatment or prevention guidance for industry. 2021. https://www.fda.gov/regulatory-information/search-fda-guidance-documents...
    1. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292–2300. - PMC - PubMed
    1. Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021;8 - PMC - PubMed
    1. Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. The prevalence of gastrointestinal symptoms, abnormal liver function, digestive system disease and liver disease in COVID-19 Infection: A systematic review and meta-analysis. J Clin Gastroenterol. 2021;55:67–76. - PMC - PubMed